Benitec licenses technology to French transgenic rat firm
Tuesday, 22 March, 2005
Benitec (ASX:BLT) has granted a worldwide, non-exclusive commercial licence to French company genOway to develop transgenic rodents with Benitec's proprietary DNA-directed RNA-inferference technology (ddRNAi).
Under the agreement, genOway will be free to provide customers with advanced in vivo RNAi technologies to facilitate drug discovery and development, from target validation through to safety studies.
Benitec announced today that GenOway will pay Benitec an up-front licence fee and pay ongoing royalties, but it did not disclose details of the agreement.
GenOway is widely regarded in Europe as a leader in creating advanced mouse and rat models for basic research and drug discovery, Benitec said. The company holds IP rights to multiple knockout and knock-in processes for developing animal models. It also offers a range of solutions for both gene expression and inactivation in rodent modes.
Babies of stressed mothers likely to get their teeth earlier
Maternal stress during pregnancy can speed up the timing of teeth eruption, which may be an early...
Customised immune cells used to fight brain cancer
Researchers have developed CAR-T cells — ie, genetically modified immune cells manufactured...
Elevated blood protein levels predict mortality
Proteins that play key roles in the development of diseases such as cancer and inflammation may...
